Benitec Biopharma Inc. (BNTC) Stock Price & Analysis
Benitec Biopharma Inc. (BNTC) rose 0.26% to USD 11.47 as of July 26, 2026 at 19:03 UTC, according to Nexqual real-time market data.
BNTC last closed at USD 11.44; the session ranged USD 11.22–11.82 on volume of 161,893 shares. Market capitalization is $394.04M, with a 52-week range of USD 9.85–16.76 (NCM). Source: Nexqual, July 26, 2026 at 19:03 UTC.
Key Statistics (as of July 26, 2026 at 19:03 UTC)
| Price | USD 11.47 |
|---|---|
| Change | ▲ 0.26% (up) |
| Previous Close | USD 11.44 |
| Open | USD 11.45 |
| Day Range | USD 11.22 – 11.82 |
| 52-Week Range | USD 9.85 – 16.76 |
| Volume | 161,893 shares |
| Market Cap | $394.04M |
| Exchange | NCM |
Technical Analysis (BNTC)
Nexqual's technical model rates BNTC "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 19:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.05 (neutral) |
| vs SMA50 | Below (USD 11.92) |
| MACD | -0.13 (negative) |
Analyst Ratings (BNTC)
Wall Street analysts rate BNTC "None" based on 5 analysts, with a mean price target of USD 25.8 (range USD 18–32), per Nexqual as of July 26, 2026 at 19:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 25.8 |
| High Target | USD 32 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (BNTC)
| Next Earnings Date | 2026-09-22 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.24 vs est -0.28 ▲ beat |
| 2025-12-31 | USD -0.26 vs est -0.23 ▼ miss |
| 2025-09-30 | USD -0.22 vs est -0.36 ▲ beat |
| 2025-06-30 | USD -0.42 vs est -0.31 ▼ miss |
Source: Nexqual, July 26, 2026 at 19:03 UTC.
Financials & Fundamentals (BNTC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -29.58% |
| Debt / Equity | 0.48 |
| Current Ratio | 56.82 |
| Total Cash | $184.76M |
| Total Debt | $876,000 |
| Free Cash Flow | $-7.13M |
Source: Nexqual, July 26, 2026 at 19:03 UTC.
Financial Health Score (BNTC)
Nexqual rates Benitec Biopharma Inc.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 19:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $185M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Critical — ROE -30%, ROA -19.9% |
Ownership (BNTC)
| Insider Ownership | +2.55% |
|---|---|
| Institutional Ownership | +98.58% |
| Shares Outstanding | 34.35M |
| Float | 17.93M |
| Short % of Float | +11.69% |
Source: Nexqual, July 26, 2026 at 19:03 UTC.
Leadership (BNTC)
Benitec Biopharma Inc. is led by Jerel A. Banks (age 49), Executive Chairman & CEO, per Nexqual as of July 26, 2026 at 19:03 UTC.
| Executive Chairman & CEO | Jerel A. Banks (age 49) |
|---|---|
| CFO & Secretary | Megan Joan Boston B.Com., C.A. (age 52) |
| Chief Operating Officer | Sophie Mukadam (age 44) |
| Senior Vice President of Manufacturing | Claudia Kloth |
Major Backers & Investors (BNTC)
Notable institutional backers of Benitec Biopharma Inc. include Suvretta Capital Management, LLC, Janus Henderson Group PLC, Franklin Resources, Inc., according to Nexqual as of July 26, 2026 at 19:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 33.62% |
| Janus Henderson Group PLC | 8.37% |
| Franklin Resources, Inc. | 6.92% |
| Adage Capital Partners GP L.L.C. | 6.17% |
| RA Capital Management, L.P. | 5.39% |
| Nantahala Capital Management, LLC | 4.19% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 3.94% |
| Simplify Asset Management, Inc. | 2.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.57% |
| BlackRock | 5.17% |
Source: Nexqual, July 26, 2026 at 19:03 UTC.
From Benitec Biopharma Inc.'s Latest SEC 10-K Filing (filed 2025-09-22)
Key Strengths & Strategy (as disclosed to the SEC)
- Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
- Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
- The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PULM | Pulmatrix, Inc. | USD 1.65 | ▼ 2.37% |
| CBIO | Crescent Biopharma, Inc. | USD 16.3 | ▲ 2.97% |
| AKTX | Akari Therapeutics Plc | USD 8.7 | ▼ 11.31% |
| XBIO | Xenetic Biosciences, Inc. | USD 2.64 | ▼ 1.12% |
| TENX | Tenax Therapeutics, Inc. | USD 14.53 | ▼ 1.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 19:03 UTC. This page is informational and not investment advice.